Digene Patent Litigation Settlement Could Clear Path For Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Digene will pay Enzo Biochem at least $30.5 mil. over the next five years to settle all outstanding patent litigation between the companies relating to Digene's Hybrid Capture technology - used in its flagship HC2 human papillomavirus test